This Top Medical Stock is a #1 (Strong Buy): Why It Should Be on Your Radar
Whether you're a growth, value, income, or momentum-focused investor, building a successful investment portfolio takes skill, research, and a little bit of luck.
Should You Buy #1 (Strong Buy)-Ranked Catalyst Pharmaceutical (CPRX) for Your Portfolio?
Catalyst Pharmaceutical was upgraded to the Zacks Rank #1 list on October 11, 2023. The Zacks Rank is a unique stock-rating model that helps you take advantage of earnings estimate revision trends and provides a way to get into stocks highly sought after by institutional investors.
Coral Gables, FL-based Catalyst Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company, focused on the development and commercialization of therapies targeting rare neurological diseases and disorders, such as LEMS, epilepsy (initially infantile spasms) and Tourette syndrome.
Two analysts revised their earnings estimate higher in the last 60 days for fiscal 2023, while the Zacks Consensus Estimate has increased $0.17 to $1.55 per share. CPRX also boasts an average earnings surprise of 7.2%.
Earnings are forecasted to see growth of 106.7% for the current fiscal year, and sales are expected to increase 81.5%.
Additionally, CPRX has climbed higher over the past four weeks, gaining 2.3%. The S&P 500 is down 2.4% in comparison.
Bottom Line
With a #1 (Strong Buy) ranking, positive trend in earnings estimate revisions, and strong market momentum, Catalyst Pharmaceutical could be just the stock to help your portfolio generate returns that could fund your retirement, your kids' college tuition, or your short- and long-term savings goals.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Catalyst Pharmaceuticals, Inc. (CPRX) : Free Stock Analysis Report
